Table 2.

Ad libitum smoking: Subjective response (adjusted mean ± standard error) to nicotine nasal spray by oral contraceptive use and testing week

	Oral Contraceptive Users (n=14)	Naturally Cycling Participants (n=28)	Mean Difference*	p-value**
Anticipated Low Progesterone Week
Prior to Nicotine Nasal Spray
Positive Affect	2.82 ± 0.40	3.18 ± 0.29	−0.36 ± 0.49	0.475
Negative Affect†	1.34 ± 0.34	1.70 ± 0.23	−0.36 ± 0.41	0.395
Craving	3.56 ± 0.45	2.70 ± 0.36	0.90 ± 0.46	0.061
Withdrawal†	1.04 ± 0.27	1.29 ± 0.19	−0.25 ± 0.34	0.473
Physical Symptoms	0.80 ± 0.23	0.72 ± 0.17	0.08 ± 0.25	0.741
After Nicotine Nasal Spray, Adjusted for Pre-Nasal-Spray Level
Positive Affect	3.12 ± 0.21	3.01 ± 0.17	0.11 ± 0.23	0.638
Negative Affect†	1.18 ± 0.19	1.59 ± 0.13	−0.41 ± 0.23	0.091
Craving	1.91 ± 0.29	2.62 ± 0.20	−0.71 ± 0.36	0.061
Withdrawal†	1.13 ± 0.13	1.12 ± 0.09	0.01 ± 0.16	0.940
Physical Symptoms	0.82 ± 0.08	0.68 ± 0.06	0.14 ± 0.10	0.145
Anticipated High Progesterone Week
Prior to Nicotine Nasal Spray
Positive Affect	2.59 ± 0.36	3.32 ± 0.25	−0.73 ± 0.44	0.110
Negative Affect	1.08 ± 0.27	1.33 ± 0.19	−0.25 ± 0.34	0.458
Craving	3.02 ± 0.51	2.88 ± 0.37	0.14 ± 0.61	0.825
Withdrawal†	0.80 ± 0.24	1.21 ± 0.17	−0.41 ± 0.29	0.174
Physical Symptoms	0.69 ± 0.12	0.53 ± 0.09	0.17 ± 0.14	0.243
After Nicotine Nasal Spray, Adjusted for Pre-Nasal-Spray Level
Positive Affect†	2.79 ± 0.24	3.05 ± 0.16	−0.26 ± 0.30	0.381
Negative Affect	1.16 ± 0.16	1.26 ± 0.12	−0.10 ± 0.20	0.615
Craving	1.93 ± 0.33	2.89 ± 0.23	−0.96 ± 0.40	0.024
Withdrawal†	0.91 ± 0.11	1.04 ± 0.08	−0.13 ± 0.13	0.336
Physical Symptoms	0.71 ± 0.11	0.62 ± 0.09	0.10 ± 0.13	0.446

^*(β ± Standard Error),

^**P-values are from linear mixed models with a random intercept for matched set and adjusted for FTND, and study week order (post-nasal-spray models also adjusted for pre-nasal-spray SSS level), each row is its own model,

^†Random effect variance of 0 in linear mixed model.